A Phase I Trial to Evaluate the Safety of the Addition of Alisertib to Fulvestrant in Women With Advanced Hormone Receptor Positive (HR+) Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 May 2017
At a glance
- Drugs Alisertib (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 30 Mar 2016 Status changed from suspended to active, no longer recruiting as per ClinicalTrials.gov record.
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium (n = 10).